Alnylam Pharmaceuticals (ALNY) EBIT Margin (2009 - 2026)
Alnylam Pharmaceuticals posted quarterly EBIT Margin of 23.02% for Q1 2026, down 3724.0% year-on-year from 0.64% in Q1 2025, and up 91.69% on a QoQ basis from 12.01% in Q4 2025.
Alnylam Pharmaceuticals (ALNY) has 18 years of EBIT Margin data on file, last reported at 23.02% in Q1 2026.
- For the quarter ending Q1 2026, EBIT Margin fell 3724.0% year-over-year to 23.02%; the trailing twelve-month figure through Mar 2026 stood at 17.54% (up 2401.0% YoY), and the FY2025 full-year result was 13.51%, up 2137.0% from the prior year.
- EBIT Margin for Q1 2026 stood at 23.02%, up from 12.01% in the prior quarter.
- Across five years, EBIT Margin topped out at 60.26% in Q1 2025 and bottomed at 97.63% in Q3 2022.
- The 5-year median for EBIT Margin is 15.35% (2024), against an average of 19.81%.
- The widest annual swing landed in 2023, when EBIT Margin jumped 12612 bps; it then tumbled 4385 bps in 2024.
- A 5-year view of EBIT Margin shows it stood at 56.3% in 2022, then soared by 53 bps to 26.47% in 2023, then soared by 33 bps to 17.73% in 2024, then jumped by 168 bps to 12.01% in 2025, then jumped by 92 bps to 23.02% in 2026.
- The last three EBIT Margin figures came in at 23.02% (Q1 2026), 12.01% (Q4 2025), and 29.46% (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -6.43% |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 38.10% |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 17.83% |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 23.02% |
| 10 | Revolution Medicines | 32.39 Bn | 32.39 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 23.02% |
| Dec 31, 2025 | 12.01% |
| Sep 30, 2025 | 29.46% |
| Jun 30, 2025 | -2.09% |
| Mar 31, 2025 | 60.26% |
| Dec 31, 2024 | -17.73% |
| Sep 30, 2024 | -15.35% |
| Jun 30, 2024 | 7.37% |
| Mar 31, 2024 | -8.79% |
| Dec 31, 2023 | -26.47% |
| Sep 30, 2023 | 28.50% |
| Jun 30, 2023 | -72.10% |
| Mar 31, 2023 | -46.92% |
| Dec 31, 2022 | -56.30% |
| Sep 30, 2022 | -97.63% |
| Jun 30, 2022 | -85.26% |
| Mar 31, 2022 | -68.80% |
| Dec 31, 2021 | -75.26% |
| Sep 30, 2021 | -96.83% |
| Jun 30, 2021 | -66.27% |
| Mar 31, 2021 | -104.89% |
| Dec 31, 2020 | -118.75% |
| Sep 30, 2020 | -178.94% |
| Jun 30, 2020 | -191.28% |
| Mar 31, 2020 | -211.27% |
| Dec 31, 2019 | -415.83% |
| Sep 30, 2019 | -308.73% |
| Jun 30, 2019 | -528.40% |
| Mar 31, 2019 | -567.03% |
| Dec 31, 2018 | -1,047.67% |
| Sep 30, 2018 | -12,303.43% |
| Jun 30, 2018 | -643.17% |
| Mar 31, 2018 | -673.11% |
| Dec 31, 2017 | -388.42% |
| Sep 30, 2017 | -735.84% |
| Jun 30, 2017 | -756.18% |
| Mar 31, 2017 | -561.77% |
| Dec 31, 2016 | -661.36% |
| Sep 30, 2016 | -781.45% |
| Jun 30, 2016 | -1,061.55% |
| Mar 31, 2016 | -1,498.00% |
| Dec 31, 2015 | -1,225.16% |
| Sep 30, 2015 | -1,238.61% |
| Jun 30, 2015 | -839.88% |
| Mar 31, 2015 | -281.72% |
| Dec 31, 2014 | -190.32% |
| Sep 30, 2014 | -411.95% |
| Jun 30, 2014 | -616.93% |
| Mar 31, 2014 | -3,251.53% |
| Dec 31, 2013 | -272.81% |
| Sep 30, 2013 | -358.51% |
| Jun 30, 2013 | -245.33% |
| Mar 31, 2013 | -52.59% |
| Dec 31, 2012 | -1,040.01% |
| Sep 30, 2012 | -108.28% |
| Jun 30, 2012 | -57.78% |
| Mar 31, 2012 | -52.91% |
| Dec 31, 2011 | -66.42% |
| Sep 30, 2011 | -59.82% |
| Jun 30, 2011 | -63.64% |
| Mar 31, 2011 | -75.02% |
| Dec 31, 2010 | -58.56% |
| Sep 30, 2010 | -31.55% |
| Jun 30, 2010 | -43.68% |
| Mar 31, 2010 | -46.03% |
| Dec 31, 2009 | -30.30% |
| Sep 30, 2009 | -39.80% |
| Jun 30, 2009 | -91.10% |